Enabling life science researchers to make groundbreaking discoveries

Exiqon combines leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Our products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, we are addressing the unmet need for a new approach to the diagnosis of cancer. We will push the frontiers of gene expression science with technologies that enable novel discoveries and drive development of targeted cancer diagnostic tools. Lars Kongsbak, President & CEO of Exiqon

Company Profile Exiqon combines leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Our products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, we are addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon markets its products directly on www.exiqon.com, or through distributors, and partners its proprietary Locked Nucleic Acids (LNA) and Anthraquinone (AQ) technologies through industry leaders. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark.

In December 2006, Exiqon A/S obtained ISO 9001:2000 certification for its quality management system standards in development, production, sales and support for products and services for gene activities analysis. Due to the broad applicability of Exiqons proprietary technologies, Exiqon has chosen the following partners for its products and technologies: Roche Diagnostics Luminex Corporation  Invitrogen Fischer Scientific International Inc.